Our mission begins with the word cure. We recognize groundbreaking research will lead us toward the cures we seek. For more than 70 years, LLS support has been instrumental in the development of nearly every breakthrough in blood cancer treatment.
CURRENT FUNDING OPPORTUNITIES:
The Academic Clinical Trials Program (ACT) is now open. Letters of Intent are due October 25, 2023.
The Translational Research Program (TRP) is now open. Letters of Intent are due October 20, 2023.
The Discovery Grant Program (DGP) is now open. Letters of Intent are due September 29, 2023.
The Career Development Program (CDP) is now open. Eligibility requests are due October 27, 2023.
Applications for the Equity in Access Research Program are now open. Letters of Intent are due September 15, 2023.
Our Research Grant portfolio contains programs that cover blood cancer research from the earliest phase of discovery science to translational research that goes from “Bench to Bedside” directly benefiting our patients. We also strongly believe that providing support to today's promising early-career scientists is fundamental to making sure that they will continue contributing to blood cancer research as tomorrow's leaders of the field.
We announce special, disease focused RFPs (requests for proposal) on a regular basis to accelerate research areas with high unmet need.
To move the needle further and faster, LLS forms partnerships with other organizations to fund meritorious blood cancer research together:
